Assessing Serum Asprosin Levels among Iraqi Individuals Diagnosed with Acromegaly

Objective: Asprosin (ASP) is a modern adipokine produced from white adipose tissue that is linked to metabolic disorders such as obesity and diabetes. Acromegalic syndrome results from excessive pituitary growth hormone (GH) secretion, leading to increased insulin-like growth factor-1 (IGF-1) production, usually due to a pituitary adenoma. The serum ASP levels were higher in acromegaly patients (AC-PTs) than in healthy controls. The aim of the study was to explore ASP levels in AC-PTs compared with healthy controls, considering gender, diabetes status, treatment duration, and hypertension. Materials and Methods: Fifty AC-PTs with different body mass index, sex, age, diabetes, and blood pressure were enrolled in this study. IGF-1, GH, and fasting blood glucose (FBG) levels were measured alongside 30 healthy controls. In addition, enzyme-linked immunoassay (ELISA) was used to measure ASP. Results: There was no significant difference in ASP levels between AC-PTs and healthy controls (p>0.05). Moreover, the current study showed no statistically significant difference in ASP levels among the subgroups categorized according to the patient's gender, diabetes status, hypertension, and treatment course. Conclusion: ASP levels revealed no difference between Iraqi AC-PTs and control group; ASP is not affected by hormonal changes that are typically associated with acromegaly.